(Total Views: 316)
Posted On: 03/25/2018 8:35:17 PM
Post# of 72436
![Avatar](https://investorshangout.com/images/ProfileImages/398685088_3064_306524.png)
“Innovation has received various FDA designations, reinforcing the potential of the company’s pipeline, while also providing better odds of a drug candidate's expedited approval, often with added exclusivity protections. Almost three-in-four drugs (73%) approved by the FDA in the U.S. in 2016 received some form of expedited development and review, with one-in-three (36%) representing first-in-class status."
http://www.ipharminc.com/special-fda-designations/
1. Brilacidin-OM - Fast Track
2. Brilacidin-ABSSSI - QIDP (first-in-class)
3. Prurisol - 505(b)(2)
4. Kevetrin - Orphan Drug
http://www.ipharminc.com/special-fda-designations/
1. Brilacidin-OM - Fast Track
2. Brilacidin-ABSSSI - QIDP (first-in-class)
3. Prurisol - 505(b)(2)
4. Kevetrin - Orphan Drug
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)